Examples of anticancer therapies based on inhibitors targeting enzyme regulators of lipid metabolism are orlistat (Roche Xenical®), a FASN inhibitor administered in the treatment of breast cancer [211]; and ABC294640, a sphingosine kinase 2 and dihydroceramide desaturase inhibitor currently under an Ib/II clinical trial (ClinicalTrials.gov identifier #NCT02757326). This evidence concerns the gene FASN and breast cancer.